ATRA Forex Aktualności

Atara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLD

Atara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLD

Atara Biotherapeutics, Inc. (ATRA) and French healthcare company Pierre Fabre announced Monday that the European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
RTTNews | 777 dni temu